The effective disease-modifying effects of this drug in a mouse model based on i.c.v. infusion of ALS-CSF suggest that the NF-κB signaling pathway represents a compelling therapeutic target for sporadic ALS. The gene discussed is NFKB1; the disease is amyotrophic lateral sclerosis.